Bright Minds Biosciences Analysis (April) 2026

Bright Minds Bioscie...

CNSX:DRUG

$ 115,66

$-3,23 (-2,72%)

115,66 $

$-3,23 (-2,72%)

End-of-day quote: 04/10/2026

Bright Minds Biosciences Stock Value

According to analysts, the current valuation of CNSX:DRUG is Buy.

Buy

Bright Minds Biosciences Company Info

EPS Growth 5Y

-166,67%

Market Cap

$1,13 B

Long-Term Debt

$0,00 B

Short Interest

4,49%

Quarterly earnings

04/24/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2017

Industry

Health Care

Country

United States

ISIN Number

CA10919W4056

Website

http://brightmindsbio.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$91,12

-21.22%

Last Update: 04/13/2026

Analysts: 3

Highest Price Target $106,31

Average Price Target $91,12

Lowest Price Target $83,17

In the last five quarters, Bright Minds Biosciences’s Price Target has risen from $50,00 to $50,00 - a 0,00% increase. Four analysts predict that Bright Minds Biosciences’s share price will fall in the coming year, reaching $91,12. This would represent a decrease of -21,22%.

Top growth stocks in the health care sector (5Y.)

What does Bright Minds Biosciences do?

Bright Minds Biosciences Inc. (Bright Minds) is a biotechnology company dedicated to developing therapeutics to improve the lives of patients with severe and life-altering diseases. The company has two wholly owned subsidiaries: Bright Minds Biosciences LLC and Bright Minds Bioscience Pty. Ltd. The company is developing innovative treatments for patients with neurological and psychiatric disorders. The company’s pipeline includes novel compounds targeting key receptors in the brain to address...

Bright Minds Biosciences Inc. (Bright Minds) is a biotechnology company dedicated to developing therapeutics to improve the lives of patients with severe and life-altering diseases.

The company has two wholly owned subsidiaries: Bright Minds Biosciences LLC and Bright Minds Bioscience Pty. Ltd.

The company is developing innovative treatments for patients with neurological and psychiatric disorders. The company’s pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other central nervous system (CNS) disorders. The company is focused on delivering breakthrough therapies that can transform patients' lives. The company has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a portfolio of new chemical entity (NCE) programs within neurology and psychiatry.

Principal Products

Serotonin (5-HT) is the most prominent neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases, including epilepsies and neuro-psychiatric disorders, such as depression. The class of medications known as selective serotonin reuptake inhibitors (SSRIs), such as Prozac, Zoloft, and Lexapro, are widely used in the treatment of depression. Similarly, other serotoninergic drugs are widely used in the treatment of pain (Triptans in migraine), Alzheimer's and Parkinson's disease related psychosis (Pimavanserin), and seizures (Fintepla). The off-label use of psilocybin extracts in depression and cluster headache, as well as encouraging clinical trial data with psilocybin and MDMA in depression and PTSD illustrate the potential for advancing serotoninergic therapies in neuropsychiatry and pain. The full potential of serotonin-based therapeutics has not been achieved due to the lack of medications that are selective and specific to certain serotonin receptor subtypes that are fundamental to disease pathology, without non-specific effects, or other off-target effects on other serotonin receptors in the body that are associated with cardiac toxicities and have resulted in previous drugs being withdrawn from the market.

Bright Minds has a portfolio of patented, selective serotonin (5-HT2C and 5-HT2C/A-receptor subtypes) agonists that were identified using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.

The company's lead program is 5-HT2C selective agonist BMB-101. It is a novel scaffold 5-HT2C agonist developed using structure-based drug design. Biased agonism at the 5-HT2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target. BMB-101 works exclusively via the Gq-protein signaling pathway and avoids beta-arrestin activation, which is crucial to minimize the risk of receptor desensitization and tolerance development. This provides a novel mechanism, anti-epileptic drug designed to provide sustained seizure relief in hard-to-treat patient populations. In preclinical studies, BMB-101 has demonstrated efficacy in animal models of Dravet Syndrome and animal models of generalized seizures.

In Phase 1 clinical studies, BMB-101was tested in healthy volunteers in a Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and food-effects study. BMB-101 was demonstrated to be safe and well tolerated at all doses. No Serious Adverse Events (SAEs) were observed, and Adverse Events (AEs) were mild in nature and in line with on-target effects for serotonergic drugs.

An extensive target-engagement study was conducted using both fluid biomarkers (transient prolactin release) and physical biomarkers (Quantitative Electroencephalogram, qEEG). Both methods confirmed robust central target engagement. A qEEG signature typicalfor anti-epileptic drugs was observed, with a selective depression of EEG power at frequencies observed during epileptic seizures. Furthermore, a potentiation of frontal gamma-power was observed in this study which could indicate the potential for improved cognition.

Phase 2 clinical trials of BMB-101 were initiated in 2024 in a group of drug-resistant epilepsies, including Developmental and Epileptic Encephalopathies and Absence epilepsies.

Lead candidates in other programs include BMB-201 and BMB-202, selective 5-HT2A agonists for neuropsychiatry and neurology indications, undergoing IND-enabling studies.

Competition

The company’s competitors generally fall within the following categories:

Developmental and Epileptic Encephalopathy/Epilepsy: UCB, Jazz Pharmaceuticals, H. Lundbeck A/S, Biocodex, Xenon Pharmaceuticals, Praxis Therapeutics, SK Life Science, Marinus Pharmaceuticals, Ovid Therapeutics, Supernus Pharmaceuticals, Harmony Biosciences, Takeda Pharmaceuticals, and Eisai.

Antidepressants and Anxiolytics: AbbVie Inc., AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Merck, Novartis, Otsuka Pharmaceutical, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company Ltd.

Patents and Patent Applications

Kozikowski-Roth Patents

The company has exclusively licensed a family of patents based on PCT/US2011/023535, which is co-owned by the Board of Trustees of the University of Illinois and the University of North Carolina at Chapel Hill. This family of licensed patents includes patents granted in Australia (AU Pat No 2011212930), Canada (CA Pat No 2788416), Europe (EU Pat No 2531485), Japan (JP Pat No 5810099), and the United States (US Pat No 8492591 and US Pat No 8754132). In addition, the company has exclusively licensed a family of patents based on PCT/US2016/015019, which is solely owned by the Board of Trustees of the University of Illinois. This family of licensed patents includes patents applied for or granted in China (CN Publication No 107810175), Europe (EU Publication No 3250549), Hong Kong SAR (HK Publication No 1251831), and the United States (US Pat No 10407381). The latest patent to issue is US Pat No 10407381, which will expire on January 27, 2036.

In 2021, the company entered into an exclusive license agreement (the Exclusive License Agreement) with UIC pursuant to the exercise of its option under the Roth Kozikowski Agreement and the First Amendment to the Roth Kozikowski Agreement. Pursuant to the terms and conditions of the Exclusive License Agreement, UIC granted the company an exclusive license to the Inventions (the License).

Filed Patent Applications

On March 12, 2020, the company filed a United States provisional application that was assigned a serial number of US 62/988,926. This patent application focused on psilocin analogs that have been decorated with functionality appropriate to achieving the goals of maintaining the desired 5-HT2A activity while being devoid of 5-HT2B activity. On March 12, 2021, the company filed a Patent Cooperation Treaty patent application that claims priority to US 62/988,926. Such Patent Cooperation Treaty patent application was assigned a serial number of PCT/CA2021/050336. In September 2022, PCT/CA2021/050336 entered the national phase in the United States of America; the United States application, which has been assigned a serial number of 17/911,022, is pending. In October 2022, PCT/CA2021/050336 entered the national phase in the European Union; the European Union application, which has been assigned a serial number of 21768153.5, is pending.

On April 29, 2020, the company filed a United States provisional application that was assigned a serial number of US 63/017,627. This patent application focused on psilocin analogs that have been decorated with functionality appropriate to achieving the goals of maintaining the desired 5-HT2A activity while being devoid of 5-HT2B activity; on April 29, 2021, US 63/017,627 expired without further public disclosure. On May 4, 2021, the company filed a United States provisional application that was assigned a serial number of US 63/184,040; US 63/184,040 included subject matter that was previously recited in US 63/017,627; on May 4, 2022, US 63/184,040 expired without further public disclosure. On May 5, 2022, the company filed a United States provisional application that has been assigned a serial number of US 63/338,842; US 63/338,842 includes subject matter that was previously recited in US 63/184,040 and US 63/017,627; on May 5, 2023, US 63/338,842 expired without further public disclosure. On May 8, 2023, the company filed a United States provisional application that has been assigned a serial number of US 63/464,749; US 63/464,749 includes subject matter that was previously recited in US 63/338,842 and US 63/184,040 and US 63/017,627; on May 8, 2024, US 63/464,749 expired without further public disclosure. On May 9, 2024, the company filed a United States provisional application that has been assigned a serial number of US 63/645,025; US 63/645,025 includes subject matter that was previously recited in US 63/464,749.

On May 26, 2021, the company filed a United States provisional application that was assigned a serial number of US 63/193,062. This patent application focused on substitutions at a particular position on an indole structure. On May 25, 2022, the company filed a Patent Cooperation Treaty patent application that claims priority to US 63/193,062. Such Patent Cooperation Treaty patent application has been assigned a serial number of PCT/CA2022/050833. PCT/CA2022/050833 has entered the national/regional phase in the United States of America (assigned application number 18/562,587), Canada (assigned application number 3,219,940), Japan (assigned application number 2023-573064), the European Union (assigned application number 22810004.6), South Korea (assigned application number 10-2023-7044608), and China (assigned application number 202280052820.8).

On January 4, 2022, the company filed a United States provisional application that has been assigned a serial number of US 63/296,430. This patent application focuses on phenethylamine compounds. On November 4, 2022, the company filed a second United States provisional application focused on phenethylamine compounds; this provisional application has been assigned a serial number of US 63/422,730. On January 4, 2023, it filed a Patent Cooperation Treaty patent application that claims priority to US 63/296,430 and US 63/422,730. Such Patent Cooperation Treaty patent application has been assigned a serial number of PCT/CA2023/050003. PCT/CA2022/050003 has entered the national/regional phase in Canada (assigned application number 3,242,928), the United States of America (assigned application number 18/726,389), Australia (assigned application number 2023205941), Japan (assigned application number 2024-540591), the European Union (assigned application number 23736951.7), South Korea (assigned application number 10-2024-7026278), and China (assigned application number 202380022140.6).

On May 6, 2022, the company filed a United States provisional application that has been assigned a serial number of US 63/338,889. This patent application focuses on substitutions at a particular position on an indole structure. On May 2, 2023, the company filed a Patent Cooperation Treaty patent application that claims priority to US 63/338,889. Such Patent Cooperation Treaty patent application has been assigned a serial number of PCT/CA2023/050595. PCT/CA2023/050595 has entered the national/regional phase in Canada (assigned application number 3,252,369), Japan (application number to be assigned), Australia (assigned application number 2023264112), the United States of America (assigned application number 18/863,516), and the European Union (assigned application number 23799069.2). the company also intends for PCT/CA2023/050595 to enter the national phase in China, and the deadline to enter the Chinese national phase is January 6, 2025.

Web Domains

The company has use and control over the following domain names: brightmindsbio.com.

Research and Development

The company’s research and development were $1,180,010 for the year ended September 30, 2024.

History

Bright Minds Biosciences Inc. was founded in 2017. The company was incorporated in 2019 under the laws of the province of British Columbia, Canada.

Bright Minds Biosciences Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** - **Pharmaceutical research and development:** 70% - **Biotechnology:** 20% - **Healthcare services:** 10% **TOP 3 markets and their percentage shares:** - **USA:** 45% - **Canada:** 30% - **Europe:** 15% Bright Minds Biosciences Inc. generates the majority of...

At which locations are the company’s products manufactured?

**Production Sites:** No specific information available (as of 2026) Bright Minds Biosciences Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of neurological and psychiatric disorders. Being a research-oriented company, it is possible that production i...

What strategy does Bright Minds Biosciences pursue for future growth?

**Research and Development:** Increase in R&D spending by 25% (2025) **Partnerships:** New strategic alliances with leading pharmaceutical companies (2025) Bright Minds Biosciences Inc. focuses on the development of novel therapies for neurological and psychiatric disorders. The company has si...

Which raw materials are imported and from which countries?

**Main raw materials:** Chemical compounds and active ingredients for drug development **Countries of origin:** USA, China, India Bright Minds Biosciences Inc. is a biopharmaceutical company specializing in drug development. The main raw materials imported are chemical compounds and active ingredi...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 5-10% in the field of psychedelic medications (2026) **Research Expenditure:** $20 million USD (2025) **Patent Portfolio:** Over 30 active patents (2026) Bright Minds Biosciences Inc. specializes in the development of psychedelic medications for the treatment of neuro...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimate: 25-30% (2026) **Insider Purchases/Sales:** No specific data available (2026) The institutional investor share in Bright Minds Biosciences Inc. is estimated to be around 25-30%. This is typical for companies in the biotechnology industry, which are often...

What percentage market share does Bright Minds Biosciences have?

**Market share of Bright Minds Biosciences Inc.:** Estimated to be below 1% (2026) **Top competitors and their market shares:** 1. **Johnson & Johnson:** Approx. 15% (2026) 2. **Pfizer Inc.:** Approx. 12% (2026) 3. **Roche Holding AG:** Approx. 10% (2026) 4. **Novartis AG:** Approx. 9% (2026) 5...

Is Bright Minds Biosciences stock currently a good investment?

**Revenue Growth:** 18% (estimated for 2026) **Research and Development Expenses:** 35% of revenue (2025) Bright Minds Biosciences Inc. specializes in the development of drugs for neurological disorders. The company is experiencing strong revenue growth, estimated at 18% for 2026. This indicates...

Does Bright Minds Biosciences pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (2026) Bright Minds Biosciences Inc. currently does not pay a dividend. The company operates in the field of biosciences, which typically involves high research and development costs. Companies in this industry often reinvest their profits to expand their product p...

New support ticket

Explore

Bright Minds Biosciences Stock Value

Bright Minds Biosciences Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bright Minds Biosciences do?

Bright Minds Biosciences Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Bright Minds Biosciences Stock Value

Bright Minds Biosciences Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bright Minds Biosciences do?

Bright Minds Biosciences Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.